Cambrex opens new pilot plant in Milan, Italy

Adds speed and flexibility for small-scale API production

Cambrex Corporation, the leading manufacturer of small molecule innovator and generic active pharmaceutical ingredients (APIs), has announced the validation and ISO certification of a new pilot plant at its state-of-the-art manufacturing and R&D site in Paullo (MI), Italy.

The cGMP plant, which can produce batch sizes from 1–15kg, was constructed to meet customer demand for small-scale API volumes, both for validation to support a DMF filing for Abbreviated New Drug Applications or generic registrations, and for API supply to niche markets, including ophthalmic drugs.

The new facility will also provide custom manufacturing of NCEs and intermediates for early stage drug development and clinical trials.

'We currently have a product portfolio comprising more than 70 generic APIs, which are manufactured according to cGMP for the global generic pharmaceutical industry,' commented Aldo Magnini, Managing Director, Cambrex Milan. 'We have invested in the pilot plant to expand our small-scale volume offering for customers worldwide and to give us greater speed, flexibility and capacity in this market space.'

The new facility is equipped with a hydrogenator that can operate at 30Bar and two separate lines of 150L glass-lined and stainless steel reactors. ISO 8 classified, the plant is also equipped with a static dryer, milling and micronisation capabilities. Cambrex plans a further upgrade of the pilot plant in 2017 to support production of Class 3/4 high potency products.